Early programmable valve malfunctions in pediatric hydrocephalus

Francesco T Mangano1, Jose A Menendez, Tracy Habrock

  • 1Department of Neurological Surgery, St Louis Children's Hospital, Washington University, Missouri 63110, USA.

Journal of Neurosurgery
|December 31, 2005
PubMed

Insights

Programmable valves in pediatric hydrocephalus showed an 11.1% annual malfunction rate, unlike nonprogrammable valves. This study highlights concerns about the reliability of adjustable differential pressure valves in children.

Area of Science:

  • Neurosurgery
  • Pediatric Surgery
  • Biomedical Engineering

Background:

  • Adjustable differential pressure valves are recommended for ventriculoperitoneal (VP) shunts, but clinical reliability data are limited.
  • Recent identification of malfunctioning programmable valves in pediatric shunt revisions prompted this review.

Purpose of the Study:

  • To retrospectively evaluate the clinical reliability of programmable versus nonprogrammable valve shunts in pediatric patients.
  • To determine the intrinsic malfunction rate of programmable valves in this cohort.

Main Methods:

  • Retrospective chart analysis of 100 pediatric patients with programmable valve shunts and 89 with nonprogrammable valve shunts.
  • Data collected included cause of hydrocephalus, shunt malfunction type, and cerebrospinal fluid (CSF) protein levels.
  • Follow-up ranged from 1 to 26 months (mean 9.75-10.4 months).

Main Results:

  • 35% of patients with programmable valves required shunt revision due to malfunction.
  • The intrinsic programmable valve malfunction rate was 11.1% per year, with no intrinsic malfunctions in the nonprogrammable group.
  • No significant differences in CSF protein levels or malfunction types were found between groups.

Conclusions:

  • Programmable valves demonstrated a significant annualized intrinsic malfunction rate (11.1%) compared to nonprogrammable valves.
  • Cerebrospinal fluid protein levels did not correlate with valve malfunction.
  • Further prospective, randomized studies are needed to determine specific indications and reliability of programmable valves in pediatric hydrocephalus.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
304
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
223
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
259
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
556
Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
517
Heart Valves01:16

Heart Valves

The human heart is a complex organ with an intricate system of valves that regulate blood flow. There are two main types of valves: atrioventricular (AV) valves and semilunar valves.
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
12.0K